The Quantellect read.As of Nov 19, 2026, 9 active firms cover Syndax Pharmaceuticals Inc: 9 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $33.00 to $57.00, a moderate spread. The average target of $42.00 sits 390% above the current $8.58. The rating mix has stayed broadly stable, with Buy-side ratings easing from 11 to 9 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.28 next quarter toward $-0.78 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 active firms
Buy
Strong Buy00%
Buy9100%
Neutral00%
Sell00%
Strong Sell00%
Based on 9 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$42.00
+389.5% upside
Average target across 9 active firms as of Nov 19, 2026 vs $8.58 current
Highest Target$57.00
Average Target$42.00
Lowest Target$33.00
Detailed analyst forecasts for SNDX
Showing 1–10 of 10 named analysts shown · 9 active firms in the rating projection
As of Nov 19, 2026, 9 of 9 active firms rate SNDX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SNDX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.28
Range $-0.42 – $-0.08 · 3 analysts · -42% YoY
Next period, 3 analysts expect Syndax Pharmaceuticals Inc to earn $-0.28 a share (range $-0.42 – $-0.08), versus $-0.48 a year earlier. Full-year consensus is $-2.13, growing to $-0.78 the year after.
REVENUE · NEXT QUARTER
$96.0M
Range $95.3M – $96.6M · 3 analysts · +48% YoY
Revenue is expected to reach $96.0M (range $95.3M – $96.6M), +47.9% year-over-year. Full-year consensus is $316.4M, rising to $458.8M next year.
Top analysts covering Syndax Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SNDX.
#1
Michael Schmidt
Guggenheim · Rank #4
Buy
$32.00+273.0% to target
Overall win rate
53%
+ Follow
#2
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$33.00+284.6% to target
Overall win rate
49%
+ Follow
#3
Peter Lawson
Barclays · Rank #89
Buy
$22.00+156.4% to target
Overall win rate
45%
+ Follow
#4
Anupam Rama
JP Morgan · Rank #171
Buy
$40.00+366.2% to target
Overall win rate
48%
+ Follow
#5
Andres Y. Maldonado
HC Wainwright & Co. · Rank #288
Buy
$38.00+342.9% to target
Overall win rate
39%
+ Follow
SNDX stock forecast FAQ
What is SNDX's average 12-month price target?+
The 9 active firms with a live target average $42.00 for Syndax Pharmaceuticals Inc over the next 12 months, ranging from a $57.00 high to a $33.00 low, as of Nov 19, 2026.
Is SNDX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 9 active firms as of Nov 19, 2026, 9 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for SNDX?+
The Street-high target is $57.00 (Citigroup), and the Street-low is $33.00 (UBS). The average of all 9 active-firm targets is $42.00.
How many active Wall Street firms cover SNDX?+
9 active firms have a recognized rating on Syndax Pharmaceuticals Inc as of Nov 19, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SNDX?+
Among analysts who currently cover SNDX, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Buy with a $32.00 target.
What is Syndax Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.28 per share (range $-0.42 – $-0.08) across 3 analysts. Full-year EPS is projected at $-2.13, rising to $-0.78 the following year.
How much revenue is Syndax Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $96.0M (range $95.3M – $96.6M). Full-year revenue is projected at $316.4M, growing to $458.8M next year.
Have analysts been upgrading or downgrading SNDX lately?+
As of Nov 19, 2026, 9 of 9 active firms rate SNDX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SNDX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.